The board resolved to issue the shares at a price of SEK 15 each, matching the terms established during the company's broader rights offering. This decision stems from a guarantee commitment provided by Bergs Securities in September, which included an option for the guarantor to receive compensation in shares instead of cash. By opting for this equity-based settlement, the firm retains capital for its ongoing medical technology operations.
This issuance increases the total number of SciBase shares to 14,119,787 and raises the share capital by SEK 300,000. The transaction results in a minor dilution of approximately 0.4 percent for existing shareholders. The board maintains that the subscription price was set at market terms following arm's length negotiations, ensuring the arrangement aligns with the interests of both the company and its investors.



Comments (0)
No comments yet. Be the first!